胆汁酸G蛋白偶联受体5在非病毒性肝病中的作用

周群; 张华; 刘平; 陈佳美

doi:10.3969/j.issn.1001-5256.2022.09.043

胆汁酸G蛋白偶联受体5在非病毒性肝病中的作用

DOI: 10.3969/j.issn.1001-5256.2022.09.043

周群^{1, 2},
张华¹,
刘平^{1, 2, , ,},
陈佳美^1, , ,

1.
上海中医药大学附属曙光医院，上海市中医药研究院肝病研究所，肝肾疾病病证教育部重点实验室，上海市中医临床重点实验室，上海 201203
2.
上海中医药大学交叉科学研究院，上海市中医药化学生物学前沿基地，上海 201203

基金项目:

国家自然科学基金重点项目 (82130120);

国家自然科学基金 (81973613);

上海市青年科技启明星计划项目 (19QA1408900)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：周群负责查阅文献，撰写综述；张华负责修改论文；刘平、陈佳美负责拟定写作思路，修改审校文章及最后定稿。

详细信息

通信作者:
刘平，liuliver@vip.sina.com

陈佳美，cjm0102@126.com

计量
- 文章访问数: 421
- HTML全文浏览量: 113
- PDF下载量: 28
- 被引次数: 0
出版历程
- 收稿日期: 2022-01-31
- 录用日期: 2022-03-05
- 出版日期: 2022-09-20

Role of Takeda G protein-coupled receptor-5 in non-viral liver diseases

Qun ZHOU^{1, 2},
Hua ZHANG¹,
Ping LIU^{1, 2
, ,
,},
Jiamei CHEN^{1
, ,
,}

1.
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine; Institute of Liver Diseases, Shanghai University of Traditional Chinese Medicine; Key Laboratory of Liver and Kidney Diseases, Ministry of Education; Shanghai Key Laboratory of Traditional Chinese Clinical Medicine, Shanghai 201203, China
2.
Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai Frontiers Science Center of TCM Chemical Biology, Shanghai 201203, China

Research funding:

Key Program of National Natural Science Foundation of China (82130120);

National Natural Science Foundation of China (81973613);

Shanghai Rising-Star Program (19QA1408900)

More Information

Corresponding author: LIU Ping, liuliver@vip.sina.com(ORCID: 0000-0002-6152-4508); CHEN Jiamei, cjm0102@126.com(ORCID: 0000-0001-9808-9610)

摘要

摘要: 非病毒性肝病主要包括非酒精性脂肪性肝病、酒精性肝病、自身免疫性肝病和胆汁淤积性肝病等，近年来患病率呈上升趋势。胆汁酸G蛋白偶联受体5(TGR5)隶属于G蛋白偶联受体超家族，由初级和次级胆汁酸激活，在胆汁酸稳态、基础代谢、能量平衡和减轻炎症反应等方面均发挥重要的调控作用，是多种疾病的潜在治疗靶点。越来越多的证据表明，TGR5可改善肝脏胆汁酸及糖脂代谢，减轻肝脏炎症反应，减少肝脂肪变性，从而发挥保护肝脏的作用。本文就目前TGR5在非病毒性肝病领域中的基础研究进展作一综述，期冀对TGR5的研究发展有所补益。
- 胆汁酸G蛋白偶联受体5 /
- 非酒精性脂肪性肝病 /
- 肝疾病, 酒精性 /
- 胆管炎, 硬化性
Abstract: Non-viral liver diseases mainly include nonalcoholic fatty liver disease, alcoholic liver disease, autoimmune liver disease, and cholestatic liver disease, and the prevalence rate of non-viral liver diseases tends to increase in recent years. Takeda G protein-coupled receptor-5 (TGR5) belongs to the G protein-coupled receptor superfamily and is activated by primary and secondary bile acids. TGR5 plays an important regulatory role in bile acid homeostasis, basal metabolism, energy balance, and alleviation of inflammatory response and is a potential therapeutic target for many diseases. An increasing number of evidence has shown that TGR5 exerts a protective effect on the liver by improving bile acid and glycolipid metabolism in liver, alleviating liver inflammation, and reducing liver steatosis. This article reviews the recent advances in the basic research on TGR5 in the field of non-viral liver diseases, so as to facilitate the development of the research on TGR5.
- Takeda G Protein-Coupled Receptor-5 /
- Non-Alcoholic Fatty Liver Disease /
- Liver Diseases, Alcoholic /
- Cholangitis, Sclerosing

HTML全文

参考文献(57)

[1]	MARUYAMA T, MIYAMOTO Y, NAKAMURA T, et al. Identification of membrane-type receptor for bile acids (M-BAR)[J]. Biochem Biophys Res Commun, 2002, 298(5): 714-719. DOI: 10.1016/s0006-291x(02)02550-0.
[2]	DUBOC H, TACHÉ Y, HOFMANN AF. The bile acid TGR5 membrane receptor: from basic research to clinical application[J]. Dig Liver Dis, 2014, 46(4): 302-312. DOI: 10.1016/j.dld.2013.10.021.
[3]	SCHAAP FG, TRAUNER M, JANSEN PL. Bile acid receptors as targets for drug development[J]. Nat Rev Gastroenterol Hepatol, 2014, 11(1): 55-67. DOI: 10.1038/nrgastro.2013.151.
[4]	CHIANG JYL, FERRELL JM. Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy[J]. Am J Physiol Gastrointest Liver Physiol, 2020, 318(3): G554-G573. DOI: 10.1152/ajpgi.00223.2019.
[5]	DONEPUDI AC, BOEHME S, LI F, et al. G-protein-coupled bile acid receptor plays a key role in bile acid metabolism and fasting-induced hepatic steatosis in mice[J]. Hepatology, 2017, 65(3): 813-827. DOI: 10.1002/hep.28707.
[6]	PATHAK P, LIU H, BOEHME S, et al. Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism[J]. J Biol Chem, 2017, 292(26): 11055-11069. DOI: 10.1074/jbc.M117.784322.
[7]	KUMAR DP, ASGHARPOUR A, MIRSHAHI F, et al. Activation of transmembrane bile acid receptor TGR5 modulates pancreatic islet α cells to promote glucose homeostasis[J]. J Biol Chem, 2016, 291(13): 6626-6640. DOI: 10.1074/jbc.M115.699504.
[8]	SASAKI T, WATANABE Y, KUBOYAMA A, et al. Muscle-specific TGR5 overexpression improves glucose clearance in glucose-intolerant mice[J]. J Biol Chem, 2021, 296: 100131. DOI: 10.1074/jbc.RA120.016203.
[9]	POLS TW, NOMURA M, HARACH T, et al. TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading[J]. Cell Metab, 2011, 14(6): 747-757. DOI: 10.1016/j.cmet.2011.11.006.
[10]	LI S, QIU M, KONG Y, et al. Bile acid G protein-coupled membrane receptor TGR5 modulates aquaporin 2-mediated water homeostasis[J]. J Am Soc Nephrol, 2018, 29(11): 2658-2670. DOI: 10.1681/ASN.2018030271.
[11]	VELAZQUEZ-VILLEGAS LA, PERINO A, LEMOS V, et al. TGR5 signalling promotes mitochondrial fission and beige remodelling of white adipose tissue[J]. Nat Commun, 2018, 9(1): 245. DOI: 10.1038/s41467-017-02068-0.
[12]	LIANG H, MATEI N, MCBRIDE DW, et al. TGR5 activation attenuates neuroinflammation via Pellino3 inhibition of caspase-8/NLRP3 after middle cerebral artery occlusion in rats[J]. J Neuroinflammation, 2021, 18(1): 40. DOI: 10.1186/s12974-021-02087-1.
[13]	HU X, YAN J, HUANG L, et al. INT-777 attenuates NLRP3-ASC inflammasome-mediated neuroinflammation via TGR5/cAMP/PKA signaling pathway after subarachnoid hemorrhage in rats[J]. Brain Behav Immun, 2021, 91: 587-600. DOI: 10.1016/j.bbi.2020.09.016.
[14]	JIN P, DENG S, TIAN M, et al. INT-777 prevents cognitive impairment by activating Takeda G protein-coupled receptor 5 (TGR5) and attenuating neuroinflammation via cAMP/ PKA/ CREB signaling axis in a rat model of sepsis[J]. Exp Neurol, 2021, 335: 113504. DOI: 10.1016/j.expneurol.2020.113504.
[15]	DENG L, CHEN X, ZHONG Y, et al. Activation of TGR5 partially alleviates high glucose-induced cardiomyocyte injury by inhibition of inflammatory responses and oxidative stress[J]. Oxid Med Cell Longev, 2019, 2019: 6372786. DOI: 10.1155/2019/6372786.
[16]	WANG J, ZHANG J, LIN X, et al. DCA-TGR5 signaling activation alleviates inflammatory response and improves cardiac function in myocardial infarction[J]. J Mol Cell Cardiol, 2021, 151: 3-14. DOI: 10.1016/j.yjmcc.2020.10.014.
[17]	LI J, CHENG R, WAN H. Overexpression of TGR5 alleviates myocardial ischemia/reperfusion injury via AKT/GSK-3β mediated inflammation and mitochondrial pathway[J]. Biosci Rep, 2020, 40(1): BSR20193482. DOI: 10.1042/BSR20193482.
[18]	ZHUANG L, DING W, ZHANG Q, et al. TGR5 attenuated liver ischemia-reperfusion injury by activating the Keap1-Nrf2 signaling pathway in mice[J]. Inflammation, 2021, 44(3): 859-872. DOI: 10.1007/s10753-020-01382-y.
[19]	ZHOU H, ZHOU S, SHI Y, et al. TGR5/Cathepsin E signaling regulates macrophage innate immune activation in liver ischemia and reperfusion injury[J]. Am J Transplant, 2021, 21(4): 1453-1464. DOI: 10.1111/ajt.16327.
[20]	LI ZY, ZHOU JJ, LUO CL, et al. Activation of TGR5 alleviates inflammation in rheumatoid arthritis peripheral blood mononuclear cells and in mice with collagen Ⅱ-induced arthritis[J]. Mol Med Rep, 2019, 20(5): 4540-4550. DOI: 10.3892/mmr.2019.10711.
[21]	HU J, WANG C, HUANG X, et al. Gut microbiota-mediated secondary bile acids regulate dendritic cells to attenuate autoimmune uveitis through TGR5 signaling[J]. Cell Rep, 2021, 36(12): 109726. DOI: 10.1016/j.celrep.2021.109726.
[22]	MERLEN G, BIDAULT-JOURDAINNE V, KAHALE N, et al. Hepatoprotective impact of the bile acid receptor TGR5[J]. Liver Int, 2020, 40(5): 1005-1015. DOI: 10.1111/liv.14427.
[23]	MERLEN G, KAHALE N, URSIC-BEDOYA J, et al. TGR5-dependent hepatoprotection through the regulation of biliary epithelium barrier function[J]. Gut, 2020, 69(1): 146-157. DOI: 10.1136/gutjnl-2018-316975.
[24]	ESLAM M, SANYAL AJ, GEORGE J, et al. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology, 2020, 158(7): 1999-2014. e1. DOI: 10.1053/j.gastro.2019.11.312.
[25]	SHI Y, SU W, ZHANG L, et al. TGR5 regulates macrophage inflammation in nonalcoholic steatohepatitis by modulating NLRP3 inflammasome activation[J]. Front Immunol, 2020, 11: 609060. DOI: 10.3389/fimmu.2020.609060.
[26]	DING L, SOUSA KM, JIN L, et al. Vertical sleeve gastrectomy activates GPBAR-1/TGR5 to sustain weight loss, improve fatty liver, and remit insulin resistance in mice[J]. Hepatology, 2016, 64(3): 760-773. DOI: 10.1002/hep.28689.
[27]	FINN PD, RODRIGUEZ D, KOHLER J, et al. Intestinal TGR5 agonism improves hepatic steatosis and insulin sensitivity in Western diet-fed mice[J]. Am J Physiol Gastrointest Liver Physiol, 2019, 316(3): G412-G424. DOI: 10.1152/ajpgi.00300.2018.
[28]	ARAB JP, KARPEN SJ, DAWSON PA, et al. Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives[J]. Hepatology, 2017, 65(1): 350-362. DOI: 10.1002/hep.28709.
[29]	SINGAL AK, BATALLER R, AHN J, et al. ACG clinical guideline: Alcoholic liver disease[J]. Am J Gastroenterol, 2018, 113(2): 175-194. DOI: 10.1038/ajg.2017.469.
[30]	SPATZ M, CIOCAN D, MERLEN G, et al. Bile acid-receptor TGR5 deficiency worsens liver injury in alcohol-fed mice by inducing intestinal microbiota dysbiosis[J]. JHEP Rep, 2021, 3(2): 100230. DOI: 10.1016/j.jhepr.2021.100230.
[31]	FAN M, WANG Y, JIN L, et al. Bile acid-mediated activation of brown fat protects from alcohol-induced steatosis and liver injury in mice[J]. Cell Mol Gastroenterol Hepatol, 2022, 13(3): 809-826. DOI: 10.1016/j.jcmgh.2021.12.001.
[32]	IRACHETA-VELLVE A, CALENDA CD, PETRASEK J, et al. FXR and TGR5 agonists ameliorate liver injury, steatosis, and inflammation after binge or prolonged alcohol feeding in mice[J]. Hepatol Commun, 2018, 2(11): 1379-1391. DOI: 10.1002/hep4.1256.
[33]	DYSON JK, BEUERS U, JONES D, et al. Primary sclerosing cholangitis[J]. Lancet, 2018, 391(10139): 2547-2559. DOI: 10.1016/S0140-6736(18)30300-3.
[34]	VESTERHUS M, KARLSEN TH. Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities[J]. J Gastroenterol, 2020, 55(6): 588-614. DOI: 10.1007/s00535-020-01681-z.
[35]	KEITEL V, REICH M, HÄUSSINGER D. TGR5: pathogenetic role and/or therapeutic target in fibrosing cholangitis?[J]. Clin Rev Allergy Immunol, 2015, 48(2-3): 218-225. DOI: 10.1007/s12016-014-8443-x.
[36]	REICH M, SPOMER L, KLINDT C, et al. Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis[J]. J Hepatol, 2021, 75(3): 634-646. DOI: 10.1016/j.jhep.2021.03.029.
[37]	BAGHDASARYAN A, CLAUDEL T, GUMHOLD J, et al. Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2^-/- (Abcb4^-/-) mouse cholangiopathy model by promoting biliary HCO₃^- output[J]. Hepatology, 2011, 54(4): 1303-1312. DOI: 10.1002/hep.24537.
[38]	YOKODA RT, RODRIGUEZ EA. Review: Pathogenesis of cholestatic liver diseases[J]. World J Hepatol, 2020, 12(8): 423-435. DOI: 10.4254/wjh.v12.i8.423.
[39]	KEITEL V, HÄUSSINGER D. Role of TGR5 (GPBAR1) in liver disease[J]. Semin Liver Dis, 2018, 38(4): 333-339. DOI: 10.1055/s-0038-1669940.
[40]	BIDAULT-JOURDAINNE V, MERLEN G, GLÉNISSON M, et al. TGR5 controls bile acid composition and gallbladder function to protect the liver from bile acid overload[J]. JHEP Rep, 2020, 3(2): 100214. DOI: 10.1016/j.jhepr.2020.100214.
[41]	KLINDT C, REICH M, HELLWIG B, et al. The G protein-coupled bile acid receptor TGR5 (Gpbar1) modulates endothelin-1 signaling in liver[J]. Cells, 2019, 8(11): 1467. DOI: 10.3390/cells8111467.
[42]	YANG H, LUO F, WEI Y, et al. TGR5 protects against cholestatic liver disease via suppressing the NF-κB pathway and activating the Nrf2/HO-1 pathway[J]. Ann Transl Med, 2021, 9(14): 1158. DOI: 10.21037/atm-21-2631.
[43]	RAO J, YANG C, YANG S, et al. Deficiency of TGR5 exacerbates immune-mediated cholestatic hepatic injury by stabilizing the β-catenin destruction complex[J]. Int Immunol, 2020, 32(5): 321-334. DOI: 10.1093/intimm/dxaa002.
[44]	GUTIÉRREZ-REBOLLEDO GA, SIORDIA-REYES AG, MECKES-FISCHER M, et al. Hepatoprotective properties of oleanolic and ursolic acids in antitubercular drug-induced liver damage[J]. Asian Pac J Trop Med, 2016, 9(7): 644-651. DOI: 10.1016/j.apjtm.2016.05.015.
[45]	MACZEWSKY J, KAISER J, GRESCH A, et al. TGR5 activation promotes stimulus-secretion coupling of pancreatic β-cells via a PKA-dependent pathway[J]. Diabetes, 2019, 68(2): 324-336. DOI: 10.2337/db18-0315.
[46]	RAJAGOPAL S, KUMAR DP, MAHAVADI S, et al. Activation of G protein-coupled bile acid receptor, TGR5, induces smooth muscle relaxation via both Epac-and PKA-mediated inhibition of RhoA/Rho kinase pathway[J]. Am J Physiol Gastrointest Liver Physiol, 2013, 304(5): G527-G535. DOI: 10.1152/ajpgi.00388.2012.
[47]	XUE C, LI Y, LV H, et al. Oleanolic acid targets the gut-liver axis to alleviate metabolic disorders and hepatic steatosis[J]. J Agric Food Chem, 2021, 69(28): 7884-7897. DOI: 10.1021/acs.jafc.1c02257.
[48]	LIU J, WANG X, LIU R, et al. Oleanolic acid co-administration alleviates ethanol-induced hepatic injury via Nrf-2 and ethanol-metabolizing modulating in rats[J]. Chem Biol Interact, 2014, 221: 88-98. DOI: 10.1016/j.cbi.2014.07.017.
[49]	LIU J, LU YF, WU Q, et al. Oleanolic acid reprograms the liver to protect against hepatotoxicants, but is hepatotoxic at high doses[J]. Liver Int, 2019, 39(3): 427-439. DOI: 10.1111/liv.13940.
[50]	MLALA S, OYEDEJI AO, GONDWE M, et al. Ursolic acid and its derivatives as bioactive agents[J]. Molecules, 2019, 24(15): 2751. DOI: 10.3390/molecules24152751.
[51]	SUNDARESAN A, RADHIGA T, PUGALENDI KV. Effect of ursolic acid and Rosiglitazone combination on hepatic lipid accumulation in high fat diet-fed C57BL/6J mice[J]. Eur J Pharmacol, 2014, 741: 297-303. DOI: 10.1016/j.ejphar.2014.07.032.
[52]	CHENG J, LIU Y, LIU Y, et al. Ursolic acid alleviates lipid accumulation by activating the AMPK signaling pathway in vivo and in vitro[J]. J Food Sci, 2020, 85(11): 3998-4008. DOI: 10.1111/1750-3841.15475.
[53]	YAN X, REN X, LIU X, et al. Dietary ursolic acid prevents alcohol-induced liver injury via gut-liver axis homeostasis modulation: The key role of microbiome manipulation[J]. J Agric Food Chem, 2021, 69(25): 7074-7083. DOI: 10.1021/acs.jafc.1c02362.
[54]	HORIBA T, KATSUKAWA M, MITA M, et al. Dietary obacunone supplementation stimulates muscle hypertrophy, and suppresses hyperglycemia and obesity through the TGR5 and PPARγ pathway[J]. Biochem Biophys Res Commun, 2015, 463(4): 846-852. DOI: 10.1016/j.bbrc.2015.06.022.
[55]	DING L, YANG Q, ZHANG E, et al. Notoginsenoside Ft1 acts as a TGR5 agonist but FXR antagonist to alleviate high fat diet-induced obesity and insulin resistance in mice[J]. Acta Pharm Sin B, 2021, 11(6): 1541-1554. DOI: 10.1016/j.apsb.2021.03.038.
[56]	JIANG LS, LI W, ZHUANG TX, et al. Ginsenoside ro ameliorates high-fat diet-induced obesity and insulin resistance in mice via activation of the G protein-coupled bile acid receptor 5 pathway[J]. J Pharmacol Exp Ther, 2021, 377(3): 441-451. DOI: 10.1124/jpet.120.000435.
[57]	HE K, HU Y, MA H, et al. Rhizoma Coptidis alkaloids alleviate hyperlipidemia in B6 mice by modulating gut microbiota and bile acid pathways[J]. Biochim Biophys Acta, 2016, 1862(9): 1696-1709. DOI: 10.1016/j.bbadis.2016.06.006.